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Background: Validating the potential pathogenicity of copy number variants (CNVs) identified in genome-wide
studies of autism spectrum disorders (ASD) requires detailed assessment of case/control frequencies, inheritance
patterns, clinical correlations, and functional impact. Here, we characterize a small recurrent duplication in the
annexin A1 (ANXA1) gene, identified by the Autism Genome Project (AGP) study.
Methods: From the AGP CNV genomic screen in 2,147 ASD individuals, we selected for characterization an ANXA1 gene
duplication that was absent in 4,964 population-based controls. We further screened the duplication in a follow-up
sample including 1,496 patients and 410 controls, and evaluated clinical correlations and family segregation. Sequencing
of exonic/downstream ANXA1 regions was performed in 490 ASD patients for identification of additional variants.
Results: The ANXA1 duplication, overlapping the last four exons and 3’UTR region, had an overall prevalence of 11/
3,643 (0.30%) in unrelated ASD patients but was not identified in 5,374 controls. Duplication carriers presented no
distinctive clinical phenotype. Family analysis showed neuropsychiatric deficits and ASD traits in multiple relatives
carrying the duplication, suggestive of a complex genetic inheritance. Sequencing of exonic regions and the 3’UTR
identified 11 novel changes, but no obvious variants with clinical significance.
Conclusions: We provide multilevel evidence for a role of ANXA1 in ASD etiology. Given its important role as mediator
of glucocorticoid function in a wide variety of brain processes, including neuroprotection, apoptosis, and control of the
neuroendocrine system, the results add ANXA1 to the growing list of rare candidate genetic etiological factors for ASD.
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Family and twin studies strongly support a genetic pre-
disposition for autism spectrum disorders (ASD), a neu-
rodevelopmental disorder characterized by deficits in
social interaction, communication, and repetitive behav-
iour [1,2]. However, no genes capable of explaining the
majority of cases have been identified to date.
While a prevalent hypothesis has been that ASD risk
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reproduction in any medium, provided the orvariants, each with a small effect on disorder risk [1,2],
in recent years candidate gene studies, genome-wide
array screenings, and exome sequencing have brought
rare variants to the attention of researchers [2-6]. Rare
mutations in specific genes segregating with disorders in
families with ASD and/or intellectual disability (ID) have
been reported, including SHANK3, NLGN3 and 4,
NRXN1, and many others [7-9]. More recently, exome se-
quencing has uncovered variants in other genes, such as
CHD8, GRIN2B, and SCN1A, in ASD individuals [10-12].
Studies from large research groups such as the Autism
Genome Project (AGP) international consortium, have
highlighted the importance of highly penetrant, rare sub-
microscopic deletions and duplications, designated copy
number variants (CNVs), in autism etiology [13,14]. TheseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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frequently in the human genome, and thus can contribute
to genetic diversity and genomic evolution and influence
disease risk [13,15]. The AGP study showed that ASD pa-
tients have a significantly higher burden of rare genic
CNVs, de novo and inherited, when compared to control
subjects. The identified CNVs frequently overlapped genes
previously implicated in ASD and ID, but also implicated
novel genes like SHANK2, SYNGAP1, or DLGAP2. Interest-
ingly, target genes seemed to converge in a small number of
affected pathways, with an enrichment of CNVs disrupting
functional gene sets involved in cellular proliferation, pro-
jection, and motility as well as GTPase/Ras signalling [13].
Because CNVs frequently delete or duplicate brain
expressed genes of relevance for autism, it is reasonable
to assume that many are likely of pathogenic significance
and altogether may explain a substantial fraction of ASD
risk [16]. The rigorous assessment of the clinical conse-
quences of CNVs, however, requires the establishment,
in large population samples, of recurrence rates in pa-
tients, clinical correlations, segregation in families, com-
parison of frequencies with control databases, and
molecular and functional studies.
To assess the clinical significance of rare CNVs identi-
fied by the AGP study, we selected, for further char-
acterization, de novo or inherited CNVs that were
recurrent in ASD patients but absent or extremely rare in
population-based control datasets. Here, we report a small
recurrent CNV duplicating a segment of the annexin A1
gene (ANXA1) in ASD subjects, and its detailed char-
acterization, including frequency in patients and controls,
recurrence rates, segregation in families, and breakpoint
identification. We further describe the exonic and down-
stream region sequencing of this gene in a second ASD
sample. Annexin A1, previously known as lipocortin 1, is
a 37 kDa protein belonging to the annexin protein super-
family. Annexin A1 was initially identified as a potent
anti-inflammatory protein, mediating glucocorticoid (GC)
actions in the host defence system [17]. Its functional ac-
tivities, however, far exceed this early discovery, and in-
clude cell migration, differentiation, and proliferation,
regulation of cell death signalling, phagocytic clearance of
apoptotic cells, and carcinogenesis. Annexin A1 has been
detected in the brain, where it is thought to have a neuro-
protective and anti-inflammatory function [18], and is
strongly implicated in the regulation of the neuroendo-
crine system, in particular the hypothalamus–pituitary–
adrenal (HPA) axis control by GCs [19].
Methods
CNV identification and characterization
Discovery sample
Initial screening for rare, potentially pathogenic CNVs
was performed using data from the genome-wide CNVscan carried out by the AGP consortium [13]. CNV data
were available for 2,147 ASD patients of European an-
cestry that passed all quality control filters. These sub-
jects were recruited at centres in North America and
Europe and assessed using the Autism Diagnostic
Interview-Revised and Autism Diagnostic Observation
Schedule, as previously described [20]. The Autism Sim-
plex Collection database, established in a parallel project,
is available for part of the study dataset and includes
comprehensive clinical information with detailed diag-
nostic evaluation and neuropsychological profiling of pa-
tients and relatives. To ascertain the prevalence of the
CNVs in control individuals, a set of 4,964 population-
based controls from available databases were used for
comparison [13]. This set included 1,234 controls from
Ottawa (OHI) [21], 1,123 controls from northern
Germany (PopGen) [22], 1,287 controls recruited by the
Study of Addiction: Genetics and Environment (SAGE)
consortium [23], and 1,320 controls from the Children’s
Hospital of Philadelphia (CHOP) [24].
The patients and controls were genotyped using vari-
able SNP genotyping platforms, with the characteristics
and SNP distribution shown in Additional file 1. Patients
and their parents were genotyped with the Illumina Infi-
nium 1 M-single SNP or the Illumina 1 M-duo arrays
[25], which include 8 and 11 probes, respectively, within
the region analyzed in the present study. CNVs were
analyzed using iPattern and QuantiSNP [26] detection
algorithms as previously described [13]. The control geno-
typing data was obtained using Affymetrix Genome-Wide
Human SNP 6.0 array [21,22] and Illumina Infinium 1 M-
single SNP and 550 K BeadChip array [23,24] platforms
(Additional file 1). Calling parameters and algorithms
were the same for patients and controls, and all ANXA1
duplications were subsequently validated using other
methods. The platforms used for genotyping patients and
controls have a good coverage of at least three of the four
duplicated exons (exons 10, 11, and 12) and thus ad-
equately cover the target region (Additional file 1). The
Affymetrix Genome-Wide Human SNP 6.0 array, Illumina
Infinium 1 M-single, and Illumina 1 M-duo SNP arrays in-
clude, respectively, 6 SNPs and 3 CNV, 8 SNPs, and 11
SNPs probes within the target region. The Illumina 550 K
BeadChip array includes only 5 SNP probes, but was able
to detect the duplication in several patients from a follow-
up sample (see below) which was subsequently validated
by qPCR, indicating that this platform, with the smallest
number of probes, can adequately detect the ANXA1
duplication.
Follow-up sample
A follow-up patient sample of 1,496 subjects was screened
for the ANXA1 duplication, including individuals re-
cruited in Portugal (n = 74) [27], individuals from the
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http://www.agre.org) (n = 1,123), and non-European indi-
viduals from the AGP consortium genome-wide CNV
scan [13] (n = 299). These patients were diagnosed using
the same tools and protocols as the discovery sample. Ex-
tensive phenotypic information, including morphologic,
cognitive, and adaptive functioning and language mea-
sures were available for these patients, as well as basic
family history. Autism-related behavioural traits assessed
using the Social Responsiveness Scale (SRS) [28] and the
Personality Styles and Preferences Questionnaires (PSPQ)
[29], were available for some relatives. A total of 410
Portuguese control individuals, not self-reporting an ASD
diagnosis, were recruited from health centres and hospi-
tals throughout the country. Informed consent was ob-
tained from all families included in the discovery and
follow-up samples, and procedures had approval from in-
stitutional review boards.
Ancestry analysis
Ancestry analysis was carried out using multidimen-
sional scaling as implemented in PLINK (Purcell 2007),
utilizing 90,000 autosomal SNP genotypes that were
common between the Affymetrix Genome-Wide Human
SNP 6.0 array and the Illumina Arrays; 1,397 unrelated
HapMap3 samples (typed on the Affymetrix Genome-
Wide Human SNP 6.0 array) were used as the reference
set to infer ethnicities of the cases and controls (includ-
ing 101 Indian, 497 African, 86 Mexican, 246 Chinese,
165 CEPH, 87 African-American, 102 Italian, and 113
Japanese). Further, 1,287 controls from the SAGE con-
sortium, 1,234 from the Ottawa OHI and 1,123 controls
from the PopGen studies were plotted with the 26 pa-
tients and relatives for whom genome-wide data was
available. The CHOP control dataset was not available
for ancestry analysis.
CNV validation and screening
Putative ANXA1 duplications identified in the discovery
sample were validated by qPCR using either a pre-
designed Taqman® copy number assay (Applied Biosys-
tems, Hs01220953_cn (chr9:74973810, NCBI Build36,
hg18)) or SYBR-Green I-based real time qPCR (Roche,
catalogue # 04707516001). For the Taqman assay, all sam-
ples were tested in quadruplicate, and qPCR reactions
were performed as duplex reactions with RNase P (Ap-
plied Biosystems VIC-TAMRA dual labelled probe) as the
reference assay, according to the manufacturer’s instruc-
tions, on an Applied Biosystems 7900 HT Real Time PCR
machine. Results were analyzed using Copy Caller soft-
ware (v.1.0, Applied Biosystems, USA). SYBR-Green I-
based qPCR was performed using two independent primer
pairs designed at the ANXA1 locus and at the FOXP2
locus on chromosome 7 as a diploid control.Screening of ANXA1 duplications in the Portuguese
follow-up sample or control subjects was performed
using the same Taqman assay or by Long Range PCR
using a SequalPrep Long PCR kit (Invitrogen). Primers
were designed using Primer3 software [30]. In the
remaining follow-up population, CNVs previously iden-
tified by the AGP or by AGRE (called by PennCNV
[31] using the Illumina 550 K BeadChip [5] or Omni-1
Quad genotypes) (Geschwind lab, unpublished data)
were confirmed using SYBR-Green I-based qPCR per-
formed on a LightCycler 480 Real-Time PCR system.
RNase P was used as a reference gene and a pooled
DNA sample from 94 healthy individuals as calibrator
for relative quantification.
Breakpoint mapping
For breakpoint mapping, ANXA1 duplications were
amplified using Long Range PCR and PCR products
were sequenced in both directions using fluorescent dye
terminators (BigDye Terminator v1.1 Cycle Sequencing
Kit, Applied Biosystems, Forest City, CA, USA) and the
same PCR primers on the ABI3730xls DNA Analyzer
(Applied Biosystems).
Screening for sequence variants
Sample
Sequencing of the ANXA1 coding and downstream re-
gions was performed in a population sample of 490 ASD
Portuguese patients recruited and diagnosed as de-
scribed above, including all patients previously screened
by the AGP for CNVs. The frequency of selected vari-
ants of particular relevance was estimated in 262 healthy
blood donors untested for ASD, with no family history
of neuropsychiatric diseases, recruited in Portugal.
Sequencing of coding region and exon/intron boundaries
The 13 exons, the corresponding exon/intron boundaries
and two conserved non-coding regions (chr9:74957159–
74957417; chr9:74968961–74969803, NCBI Build36, hg18)
of the ANXA1 gene were sequenced using Roche 454 mas-
sively parallel DNA sequencing. Oligonucleotide primers,
tagged with sequencing adaptors and different multiplex
identifiers (MIDs) of 10 nucleotide bases, were designed
for amplification of 21 ANXA1 gene fragments (average
length of 390 bp) using Primer3 [30] and OligoExplorer
(Gene Link) software.
Genomic DNA of the patients was accurately quantified
by fluorimetry (Quanti-iT PicoGreen dsDNA Assay Kit,
Invitrogen) and then grouped in nine equimolar pools.
The nine pools were independently used as templates for
amplification of the 21 fragments using primers tagged
with different MIDs. Amplification reactions, in a total of
189, were performed with FastStart High Fidelity Taq
DNA Polymerase (Roche). The amplicons were purified
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in an automated capillary electrophoresis system (Caliper
Life Sciences), quantified by use of PicoGreen dsDNA
quantitation reagent, and mixed in equimolar pools for
clonal amplification by emulsion PCR.
Resulting DNA library beads were loaded into the
wells of a PicoTiterPlate device and run in the Genome
Sequencer FLX Instrument. Nucleotide reads obtained
by massively parallel sequencing were aligned to the
reference sequence using Amplicon Variant Analyzer
software (Roche). Upon identification of predicted differ-
ences between reads and reference, the variants were
further analyzed taking into account the following cri-
teria to select high confidence variants: i) the number of
reads harbouring the alteration was above the expected
value for one allele (one heterozygous individual) in the
forward or in the reverse reads and ii) the alteration was
detected with both forward and reverse nucleotide reads.
Selected variants with increased frequency in cases vs.
control databases were subsequently individually geno-
typed using Taqman Custom genotyping assays in an
ABI PRISM 7900 HT sequence detector system (Applied
Biosystems) or Sequenom IPLEX assays with allele de-
tection by mass spectroscopy, using Sequenom MassAR-
RAY technology (Sequenom, San Diego, CA, USA). For
the later, primer sequences were designed using Seque-
nom’s MassARRAY Design 3.0 Software and are avail-
able upon request.
Downstream gene region sequencing
The 3’ region of ANXA1 (chr9:74975115–74978071,
NCBI Build36, hg18) was sequenced by Sanger sequen-
cing (primers available upon request). Contigs were as-
sembled and sequences were aligned using the GAP
program v4.11.2 from Staden package [32].
Bioinformatic prediction of variant effect
Functional impact of novel unique ASD variants was
assessed using several prediction tools. Human Splicing
Finder [33] and ESE-FINDER [34] were used to investi-
gate potential effects on splicing. Putative changes in
transcription factor and microRNA binding sites were
assessed using TRANSFAC [35] and miRANDA [36], re-
spectively. Conservation of orthologous positions across
diverse species was investigated using Phastcons [37]
and overlap with experimental regulatory features was
examined on the UCSC Genome browser [38].
Results
The ANXA1 gene includes 13 exons, encoding four protein-
coding transcripts (ENST00000257497, ENST00000376911,
ENST00000415424 and ENST00000456643), the largest
of which is transcribed from all 13 exons. A duplication
encompassing the last four exons of the ANXA1 gene wasidentified in 5 out of 2,147 unrelated patients from the
AGP whole genome study (Families 1–5 in Figure 1). In
4,964 population-based controls from available databases,
we did not find this duplication (P = 0.0025). Ancestry
analysis (Additional file 2) clustered together the 5 AGP
patients presenting the duplication with 3,558 European
samples from the SAGE, PopGen, and OHI control popu-
lations. Restricting the analysis to these ancestry-matched
cases and controls, we still found a significant difference
in the frequency of the duplication between cases and
controls (P = 0.0075).
In a follow-up sample including 1,496 ASD patients
and 410 control subjects, the ANXA1 duplication was
detected in 6 unrelated affected individuals (from Fam-
ilies 6–11 in Figure 1) and none of the controls. Ances-
try analysis of these subjects showed that most patients
and relatives from the AGRE dataset were spread with
non-European SAGE and OHI controls, with a few over-
lapping with Mexican populations, as expected since
some of these patients are Caucasians of Hispanic ethni-
city (Additional file 2).
The overall prevalence of the ANXA1 duplications was
estimated at 11/3,643 (~0.30%) in unrelated ASD pa-
tients, in contrast with 0/5,374 in controls (P = 4.64 ×
105). Both the patient, relative, and control samples had
a heterogeneous ancestry, and therefore we did not find
evidence for a population effect that could explain the
discrepancy of frequency of ANXA1 duplication in pa-
tients and controls.
No distinctive clinical phenotype in ANXA1 duplication
carriers
The 13 patients in 11 families identified with the dupli-
cation met criteria for autism or ASD diagnosis (Table 1),
although the clinical phenotype of the patients carrying
the duplication was heterogeneous. Intellectual level
ranged from normal in 2 patients to moderate ID in 5
subjects (in 4 patients IQ level was not known). Regarding
language function, 9 patients were verbal, but 5 of these
presented phrase speech delay, while the remaining 4 pre-
sented with severe language impairment, most using only
isolated words. Other language abnormalities, such as ar-
ticulation problems, abnormal prosody and modulation,
stuttering, hyperlexia or apraxia were less common.
Neurological dysfunction such as seizures, hypotonia or
dyskinesias, as well as minor dysmorphologies and lan-
guage or developmental regression, was present in 5 of
the patients. Three patients showed other associated prob-
lems, such as mitochondrial dysfunction and gastrointes-
tinal or sleep problems.
To search for potential multiple hits that might modu-
late clinical expression, genome-wide CNVs were ana-
lyzed in the 5 individuals carrying the ANXA1 variant
for which this data was available. No additional CNVs
Family 1
001
Dup.
002
101 102
Dup.
201
Dup.
202
Dup.
Family 2
001
Dup.
002
101 102
Dup.
201
Dup.
202
untested
Family 3
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001
Dup.
002
Dup.
101
Dup.
201
Dup.
Family 4
101
Dup.
102
201
Dup.
202
Family 6
001 002
102
Dup.
101
203
Dup.
003
untested
004
untested
201 202
Dup.
Family 7
101 102
Dup.
201
Dup.
202
untested
203
untested
Family 8
101 102
Dup.
201
Dup.
202
untested
Family 5
Maternal cousin w/ schizophrenia. 
Maternal anxiety symptoms. Maternal aunt w/ psychiatric problems and addiction. 
201 202 203
Dup.
204
Dup.
101
Dup.
102
Dup.
Family 10
001 002
102
Dup.
101
203
003
untested
004
untested
201 202
Dup.
Family 9 Family 11
Autism Spectrum Disorder
Depression
Language/learning problems
Schizophrenia
Epilepsy
Addiction
Positive SRS and/or PSPQ
Psychiatric disease unspecified
101
Dup.
102
201
Dup.
202
Dup.
203
Dup.
Maternal cousin w/ autism. 
101
Dup.
102
201
Dup.
202
Dup.
Maternal family w/ psychiatric disease and developmental delay.
Figure 1 Pedigrees of the 11 unrelated autistic patients and their affected (n = 2) and unaffected relatives carrying the ANXA1 duplication.
Families 1–5 were part of the AGP whole genome study, while families 6–11 were identified in the follow-up study. All available relatives were tested
for the ANXA1 duplication. Dup., individuals carrying the duplication. Untested, individuals for which no DNA sample was available.
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fied that were common between these 5 individuals.
All duplications are inherited
Family analysis showed that the duplication was inher-
ited in all 13 carrier affected individuals (Figure 1). In 6
patients, the CNV was inherited from the mother, in 5
from the father, and in the remaining 2 patients, who are
monozygotic twins, both parents carried the duplication.
No consanguinity has been reported in this family, and
the twins had one copy of the duplication each. Grand-
parents were available for three families, and maternal
grandfather transmission was observed in two families (1
and 2), whereas in the third family (family 3) both pater-
nal grandparents carried the duplication (Figure 1).These grandparents were reportedly distant cousins, so
there may have been a degree of consanguinity in the
family.
Ascertainment of family history further established
that all 13 patients had a positive family history of intel-
lectual or neuropsychiatric problems, with cases of ASD,
language and learning disability, schizophrenia, depres-
sion, and addiction among first or second-degree rela-
tives (Figure 1). In the three families (1, 3, and 5) where
autism traits in parents were evaluated using the SRS
[28] and PSPQ [29] questionnaires, the transmitting par-
ent scored positive for at least one of these scales. Two
affected (family 10) and 8 unaffected siblings (families 1,
4, 6, 8, and 9) were also available for testing. Two of the
3 affected siblings from family 10 did not carry the
Table 1 Clinical phenotype of the ASD patients with the identified ANXA1 duplication
ID Sex Geographical
origin
Reported
ancestry
ASD
type
IQ level Language Motor, neurological,
and sensory
problems
Physical exam Developmental
history
Relevant medical
history
Family
type
Duplication
inheritance
Fam1_201 Male Portugal European Autism Moderate
ID
Phrase speech delay;
hyperlexia
No Normal No regression;
psychomotor
development
delayed
Possible
mitochondrial
disease; sleep
problems;
rumination
SPX Maternal
Fam2_201 Male Portugal European Autism Mild ID Abnormal speech;
only isolated words
No Normal No regression;
psychomotor
development
delayed with an
onset at 2 years
None UNK Maternal
Fam3_201 Female Portugal European ASD Normal IQ No speech delay Clumsy child Myopia No regression
and no
psychomotor
delayed
development
NA SPX Paternal
Fam4_201 Male Canada European Autism Moderate
ID
Severe language
impairment; speech
and oral motor
deficit (i.e., apraxia);
uses single words
Possible history
of seizures
Normal No regression NA UNK Paternal
Fam5_201 Male USA European Autism Mild ID Phrase speech delay No Normal No regression None SPX Maternal
Fam6_203 Male USA European Autism Moderately
impaired or
delayed
Verbal; no speech
delay; articulation
problems; abnormal
prosody and
modulation;
stuttering; extreme
to moderate low
score on PPVT
Gait abnormalities;
repetitive movements
(finger; knocking);
sensory abnormalities;
abnormal light touch;
tactile defensiveness;
dyskinesias elicited
lateral foot walking
Epicanthal folds;
left absent tragus;
café au lait
Language
regression at
15 months
Gastroesophageal
reflux; chronic
diarrhoea and
constipation;
allergies and food
sensitivity; sleep
problems
SPX Maternal
Fam7_201 Male Portugal European Autism Normal IQ No speech delay No Normal No regression;
psychomotor
development
delayed
Sleep problems UNK Maternal
Fam8_203 Female USA Hispanic/
Latino
Autism NA Verbal; phrase
speech delay
NA NA No regression NA SPX Both
Fam8_204 Female USA Hispanic/
Latino
Autism NA Verbal; phrase
speech delay
NA NA No regression NA SPX Both
Fam9_202 Male USA Hispanic/
Latino
Autism NA Verbal; phrase
speech delay
NA NA No regression NA MPX Paternal
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Table 1 Clinical phenotype of the ASD patients with the identified ANXA1 duplication (Continued)
Fam10_202 Male USA Hispanic/
Latino
Autism NA Non-verbal Gait abnormalities;
repetitive movements
(hand flapping, finger
movements, body
rocking); increased
acoustic and tactile
sensibility; tactile
defensiveness
Slanted posterior
fontanel; low set
and posterior
angulation ears;
bifid uvula; high
arched palate;
finger clinodactyly
No regression Neonatal
hyperbilirubinemia
and anaemia
MPX Maternal
Fam11_201 Male USA Hispanic/
Latino
Autism Moderately
impaired or
delayed
Verbal; no speech
delay; extreme to
moderate low score
on PPVT
NA Normal Developmental
and language
regression
NA MPX Paternal
Fam11_202 Female USA Hispanic/
Latino
Autism Moderately
impaired or
delayed
Non-verbal; phrase
speech delay;
extreme to moderate
low score on PPVT
NA Normal Regression NA MPX Paternal
PPVT, Peabody Picture Vocabulary Test; NA, no information available; SPX, simplex; MPX, multiplex; UNK, unknown.
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psychopathology both on the paternal and maternal
sides and it is thus conceivable that multiple autism-
associated variants are segregating in this sibship. Four
out of the 8 unaffected siblings also carried the duplica-
tion (families 1, 6, and 9). Nevertheless, a closer inspec-
tion of the clinical phenotype showed that 3 of the 4
unaffected siblings carrying the duplication had social
interaction or cognitive problems: a positive SRS of
clinical significance (proband’s sister in family 1), docu-
mented spelling difficulties and abnormal social beha-
viour causing parental concern (dizygotic twin in family
6), and language/speech and learning disabilities requi-
ring therapy and educational support (proband’s brother
in family 9). Only the proband’s sister in family 9 carries
the duplication but has no indication of any behavioural
problem, suggesting that incomplete penetrance and/or
modulation by other factors may occur. The remaining 4
tested siblings (in families 4, 6, 8) not presenting the
ANXA1 duplication did not have any psychopathologic
diagnosis or cognitive disability. The variability in autism
traits, psychopathology, and cognitive deficits in siblings
and parents is concordant with the heterogeneity of
symptoms in the affected duplication carriers, and more
broadly, the notion of complex genetic inheritance [39].Figure 2 Genomic characterization of ANXA1 duplication: gene locatio
whether the duplication was in tandem, using primers pointing outwards from
exons are represented in blue. A sequence of microhomology of three nucleoSame ANXA1 breakpoints in all carriers
A PCR assay with primers pointing outwards from the
location of the first and last duplicated SNP in the Illu-
mina Infinium 1 M-single SNP array confirmed that the
duplication was in tandem and in the direct orientation
(Figure 2). Sequencing of this PCR product defined the
breakpoints of the duplication and determined its size
(7,728 base pairs, spanning chr9:74970292–74978018
from NCBI Build 36, hg18; Figure 2). Although the pre-
dictions by PennCNV and QuantiSNP were not the
same for all individuals [13], breakpoints were found to
be identical in the 13 ASD probands and 15 relative car-
riers, suggesting a single ancestral event. The distal
breakpoint resides in intron 9 (chr9: 74970292; Figure 2),
while the proximal end is located 2,891 bp downstream
of the gene (chr9: 74978018; Figure 2). A sequence of
microhomology of 3 nucleotides (TCA) was present in
all the individuals at both breakpoints, and is probably
mediating the duplication (Figure 2). The haplotype ana-
lysis of a window of 44 SNPs common between the vari-
ous genotyping platforms, downstream (about 111 kb)
and upstream (about 133 kb) of the duplication, in the
10 probands with genome wide-data available, was done
by comparing the haplotypes of the probands, two by
two, and calculating the similarity for each pair. Then and structure. We performed a Long Range PCR to determine
the location of the first and last duplicated SNP. The four duplicated
tides (TCA) was also identified and is probably mediating the duplication.
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Identification of novel ANXA1 sequence variants
Exonic and splice site regions
To screen for additional variants in the ANXA1 gene
that could be conferring risk for autism, sequencing of
the 13 exons, adjacent intron boundaries and the 3’re-
gion downstream of the gene was carried out in a cohort
of 490 Portuguese ASD patients.
Exon and exon/intron boundaries were sequenced
using a DNA pooling approach. A total of 735,987 nu-
cleotide reads were obtained, corresponding to a mean
coverage of 73× per fragment per individual. Forty-two
alterations were identified by sequencing of exonic and
splice site regions, 32 of which were considered high
confidence (see Methods for criteria) and were further
considered.
Based on an increased frequency of the variant in
cases vs. control databases, 28 of the 32 variants were
selected for validation by individual genotyping in the
same ASD sample and in 262 Portuguese control indi-
viduals. Five rare variants that were not listed in SNP da-
tabases and were absent in the panel of 262 control
individuals were identified (Table 2). Four of these vari-
ants were intronic and in silico analysis did not deter-
mine any putative functional role; one variant was
located in the region upstream of the gene. This latter
variant mapped to a conserved residue 48 bp upstream
of the transcription start site and overlapped with several
experimentally confirmed regulatory features, such as a
DNA hypersensitivity cluster, transcription binding sites,
and histone marks, suggesting a potential regulatory
role. TRANSFAC [35] analysis predicted potential alter-
ations in transcription factor binding sites, including the
abolishment of a binding site for the vitamin D receptor
and the creation of an orthodenticle homeobox binding
site (OTX), previously implicated in psychiatric disor-
ders [40,41]. Additionally, 3 SNPs absent in the control
sample and described as monomorphic in the Hapmap
CEU population from dbSNP were further evaluated
for a potential functional role (Table 2). One SNP
(rs2795115) was located in the 5’UTR region but no
functional alterations were predicted by in silico analysis.
Another SNP (rs10119605) was located in intron 11–12,
and a third one (rs10114350) was mapped to a splice site
sequence 7 bp upstream of exon 4, in a highly conserved
position in primates and altering an intronic splicing
enhancer.
Intergenic region
The 3’ region downstream the 3’UTR of ANXA1, which
is also included in the duplication and spans approxi-
mately 3,000 bp, has 31 nucleotide positions varyingbetween H. sapiens and P. troglodytes. Considering the
mean autosomal single nucleotide divergence between
these two species (~1.33%; [42]), which would predict 39
nucleotide changes, we observed a trend toward a puri-
fying selection in this region. Sequencing identified a
total of 21 variants, 15 of which were previously reported
SNPs and 6 were novel variants found in 8 individuals
(Table 2). One of these novel variants was exclusive of 2
monozygotic twins (both affected). One of the 6 novel var-
iants was highly conserved, however none of the 6
changes had predicted functional consequences by in
silico analysis using SNP Nexus [43] and TRANSFAC
[35], suggesting that these are probably neutral variants.
Discussion
In this study, a 7.7 kb inherited duplication on chromo-
some 9q21.13, encompassing the four last exons of the
ANXA1 gene, was identified in 11 out of 3,643 unrelated
autistic patients but in none of 5,374 healthy controls.
Ancestry analysis did not provide evidence for a popula-
tion stratification effect explaining the presence of the
duplication exclusively in patients. We also carefully
assessed the possibility that absence in control samples
from available databases was the result of false negatives
due to genotyping platform differences. SNP coverage
was adequate in the duplicated region in several of the
platforms (8 to 11 SNPs), while the array targeting the
smallest number of SNPs was able to detect the duplica-
tion in some of the patients. The intriguing duplication
frequency in cases versus its absence in controls thus
prompted us to further investigate the potential contri-
bution of variants in this gene for autism etiology.
As is commonly observed in ASD, the identified
ANXA1 duplication was not associated with a distinctive
phenotype, but patients showed a heterogeneous clinical
presentation in terms of ASD phenotype, intellectual
disability, language difficulties, neurodevelopmental re-
gression, or dysmorphic features [44-46]. A clear pattern
of transmission of the duplication with ASD was not ob-
served; however, a more meticulous analysis of the
phenotype in available relatives showed that many par-
ents and siblings carrying the duplication present a
broader autism phenotype, language disability, cognitive
deficits, or neuropsychiatric problems. One single family
included cases of ASD with and without the duplication.
However, this family was heavily burdened with neuro-
psychiatric disease on both the maternal and paternal
side, and therefore it is plausible that several etiological
factors affected the family simultaneously. In light of
present day literature, these observations suggest that a
low penetrance ANXA1 duplication may be associated
with a broader autism phenotype and co-morbidities, with
other unidentified factors interacting with the duplication
to influence its phenotypic expression. Supporting this
Table 2 Identified ANXA1 novel variants and SNPs absent in controls
Genomic
position
(hg18)
Nucleotide
change
Amino
acid
change
Location Transcript Novel/SNP Frequency
cases
Genotype In silico analysis PhastCons
(primates)
74956445 G > A – 5' of the
gene
ENST00000257497 Novel1 0.002 Homo TFBS abolished: VDR,
CAR, PXR; NF-Y, C-myb,
Crx; TFBS created: HNF6,
Nkx6-2, OTX, CdxA
0.48
74956718 CTA > Del.CTA – Intron 1–2 ENST00000257497 Novel1 0.002 Het - 0.23
74962617 C > T – 5'UTR ENST00000376911 rs27951151 0.002 Het - 0.014
74964058 T > C – intron 3–4 ENST00000257497 rs101143501 0.002 Het splice-site SNP (ENSEMBL),
ISRE down (pfSNP)
0.81
74972178 G > A – intron 10–11 ENST00000257497 Novel1 0.005 Het – 0.1
74972626 T > G – Intron 11–12 ENST00000257497 Novel1 0.002 Het – 0.18
74973075 G > C – Intron 11–12 ENST00000257497 rs101196051 0.002 Het – 0.11
74973545 T > C – Intron 11–12 ENST00000257497 Novel1 0.002 Het – NA
74975361 G > A – 3' (intergenic) – Novel 0.002 Het – 0.05
74975609 T > A – 3' (intergenic) – Novel 0.002 Het – 0.78
74975645 T > C – 3' (intergenic) – rs149272288 0.001 Het – 0.014
74975873 C > T – 3' (intergenic) – rs9792653 0.051 Het – NA
74975882 C > T – 3' (intergenic) – rs143327464 0.004 Het – NA
74976171 C > T – 3' (intergenic) – rs113627562 0.004 Het – NA
74976222 A > G – 3' (intergenic) – rs72737044 0.017 Het/Homo – 0.18
74976536 C > T – 3' (intergenic) – Novel 0.001 Het – 0.03
74976574 T > C – 3' (intergenic) – rs78798837 0.002 Het – NA
74977215 T > C – 3' (intergenic) – Novel 0.001 Het – 0.006
74977218 C > T – 3' (intergenic) – rs146061737 0.001 Het – 0.003
74977655 A > G – 3' (intergenic) – rs114240435 0.002 Het – 0
74977680 C > A – 3' (intergenic) – rs114833327 0.001 Het – NA
74977840 G > A – 3' (intergenic) – rs11143512 0.465 Het/Homo – NA
74977852 A > G – 3' (intergenic) – Novel 0.001 Het – 0.01
74977888 C > G – 3' (intergenic) – rs17653109 0.089 Het/Homo – 0.07
74977928 C > T – 3' (intergenic) – rs75260654 0.023 Het – NA
74977965 C > G – 3' (intergenic) – Novel 0.001 Het – 0.08
74977981 C > T – 3' (intergenic) – rs4443724 1 Homo – 0.003
74977990 C > T – 3' (intergenic) – rs116224215 0.007 Het – NA
74978003 C > T – 3' (intergenic) – rs4285546 0.04 Het/Homo – 0.003
1Absent in a panel of 262 control individuals; Homo, homozygous; Het, heterozygous; TFBS, transcription factor binding site; NA, not available.
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addition to clinical overlap between clinical entities in the
neuropsychiatric spectrum and ASD [28,47], shared herit-
ability and overlapping genetic factors may lead to variable
expressivity and incomplete penetrance in families of ASD
subjects [48-52].
Taking into consideration the multiple hit model pro-
posed for ASD [53,54], we searched for modulating risk
or protective genetic factors that might regulate the clin-
ical expression of the ANXA1 duplication. No other
CNV in common between these individuals was identi-
fied in the AGP whole genome study suggesting that adouble hit is a rare occurrence or that such modulating
factors are heterogeneous among these patients. Future
exome sequencing will help clarify this issue.
The exact same location of the breakpoints in all dupli-
cation carriers indicates that it is likely an ancestral event
– a hypothesis that is further supported by the similar
haplotypes flanking the duplication. The region of micro-
homology is consistent with studies showing that the
breakpoints in 40% of duplications and 70% of deletions
had regions with 1 to 30 bp of microhomology [55,56].
Extensive sequencing of exonic and regulatory regions
was carried out to identify additional sequence variants
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ology, as well as any changes co-occurring with the
inherited CNVs. Sequencing uncovered a number of
novel variants and previously reported monomorphic
SNPs absent from a panel of control individuals. One
variant upstream of the gene disrupts or creates binding
sites for transcription factors such as the vitamin D re-
ceptor and OTX, which have been implicated in psychi-
atric disorders including autism [40,41], thus potentially
modulating ANXA1 expression. Based on conservation
and functional in silico prediction tools, some of these
variants are of potential interest, although no obvious
pathogenic variants have been identified.
Abnormal post-translational processing of ANXA1 has
been previously observed in individuals with Fragile X
syndrome [57], which frequently presents with autistic
symptomatology. Expression studies will be necessary to
assess if this variant alters ANXA1 expression and to
elucidate the potential impact of the duplication. The
latest ENCODE results [58] show DNase I hypersensitiv-
ity clusters in the distal breakpoint region, suggesting a
possible disruption of a regulatory sequence. These, and
other mechanisms by which the ANXA1 duplication can
be deleterious, need to be clarified.
Annexin A1, a member of the annexin superfamily
that contains 13 calcium or calcium and phospholipid-
binding proteins, has been implicated in many diverse
cellular functions, including anti-inflammatory effects
[18,59,60], cell growth [61], apoptosis [62], membrane
fusion, endocytosis, and exocytosis [63]. The conse-
quences of annexin A1 dysregulation could therefore in-
fluence multiple pathways, some of which have been
previously linked to autism pathophysiology. Annexin
A1 was first identified as a GC-inducible protein and a
potential mediator of the anti-inflammatory actions of
these steroid hormones [17,64], ensuring an appropriate
level of activation of innate immune cells [59] and/or
transducing a stimulatory signal to promote T-cell acti-
vation. Immunological dysfunction has been a recog-
nized feature in ASD, supported by the observation of
abnormal levels of circulating brain autoantibodies and
anti-inflammatory markers as well as neuroglial activa-
tion and neuroinflammation in several brain regions in
ASD patients [65-68]. Annexin A1 also controls the
non-inflammatory phagocytosis of apoptotic neurons
and promotes the resolution of inflammatory microglial
activation [18], thus regulating neuronal apoptosis dur-
ing neurological development and the mature brain. Fur-
thermore, annexin A1 plays a fundamental role in the
regulation of the HPA axis, effecting the negative feedback
of GC at the level of the pituitary gland and hypothalamus
[69], and thus modulating the secretion of corticotrophin
(adrenocorticotropic hormone) and its hypothalamic re-
leasing hormones, corticotrophin-releasing hormone andarginine vasopressin [19]. There is evidence that the HPA
axis, as part of the limbic system which is the neural basis
for emotion and social functioning, is impaired in autistic
children [70-75]. For instance, abnormal responses of aut-
istic subject to stress as well as increased levels of cortisol
secretion and adrenocorticotropic hormone in serum of
autistic males have been reported [76-80]. Abnormalities
in corticotropic cell number and structure in male ANXA1
knockout mice further support this hypothesis [81].
Conclusions
The identification of a recurrent tandem duplication of
the ANXA1 gene in autistic patients which is not present
in a very large set of controls, supported by family obser-
vations of co-occurrence of the variant with neuro-
psychiatric disability, suggests an involvement of this
gene in the etiology of ASD. The variety of physiological
mechanisms where annexin A1 has been implicated im-
plies a fundamental role of this molecule in brain
homeostasis, with specific aspects clearly relevant for the
pathophysiology of ASD. Overall, the results described
herein constitute supporting evidence for ANXA1 as one
more etiological risk factor for ASD, warranting further
functional investigation.
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Abbreviations
AGP: Autism Genome Project; AGRE: Autism Genetics Resource Exchange;
ANXA1: Annexin A1; ASD: Autism spectrum disorders; CHOP: Children’s
hospital of Philadelphia; CNVs: Copy number variants; ENCODE: Encyclopedia
of DNA elements; GC: Glucocorticoid; HPA axis: Hypothalamus–pituitary–
adrenal axis; ID: Intellectual disability; kb/mb: kilobase/megabase;
kDa: Kilodalton; MIDs: Multiplex identifiers; OHI: Ottawa heart institute;
PSPQ: Personality styles and preferences questionnaire; SAGE: Study of
addiction, genetic and environment; SRS: Social responsiveness scale.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CTC and ICC carried out CNV validation, breakpoint mapping, segregation,
and sequence analysis. BO, JC, IS, and AFS participated in CNV and sequence
analysis and manuscript revision. KG, JKL, BT, and SW participated in CNV
and phenotypic data analysis, and manuscript revision. JA, CC, FD, SM, GO,
and WR recruited and performed the clinical assessment of patients’ and
relatives, and revised the manuscript. CM, DP, JIN, SWS, and DHG contributed
Correia et al. Molecular Autism 2014, 5:28 Page 12 of 14
http://www.molecularautism.com/content/5/1/28patient samples, participated in the interpretation of results and manuscript
revision. AMV, CTC, and ICC carried out the study design, interpretation of
data, and the drafting of the manuscript. All authors read and approved the
final manuscript.
Acknowledgments
We gratefully acknowledge the children with ASD and their families for their
collaboration. We thank the AGP investigators for sharing data, resources,
and scientific discussions. The AGP study was funded by Autism Speaks
(USA), the Health Research Board (HRB, Ireland; AUT/2006/1, AUT/2006/2,
PD/2006/48), The Medical Research Council (MRC, UK), Genome Canada/
Ontario Genomics Institute and the Hilibrand Foundation (USA). Additional
support for individual groups was provided by the US National Institutes of
Health (NIH Grants: HD055751, HD055782, HD055784, MH52708, MH55284,
MH061009, MH06359, MH066673, MH080647, MH081754, MH66766,
NS026630, NS042165, NS049261), the Canadian Institutes for Health Research
(CIHR), Assistance Publique – Hôpitaux de Paris (France), Autism Speaks UK,
Canada Foundation for Innovation/Ontario Innovation Trust, Deutsche
Forschungsgemeinschaft (Grant: Po 255/17-4) (Germany), EC Sixth FP AUTISM
MOLGEN, Fundação Calouste Gulbenkian (Portugal), Fondation de France,
Fondation FondaMental (France), Fondation Orange (France), Fondation pour
la Recherche Médicale (France), Fundação para a Ciência e Tecnologia
(Portugal), the Hospital for Sick Children Foundation and University of
Toronto (Canada), INSERM (France), Institut Pasteur (France), the Italian
Ministry of Health (convention 181 of 19 October 2001), the John P Hussman
Foundation (USA), McLaughlin Centre (Canada), Ontario Ministry of Research
and Innovation (Canada), the Seaver Foundation (USA), the Swedish Science
Council, the Centre for Applied Genomics (Canada), the Utah Autism
Foundation (USA), and the Wellcome Trust core award 075491/Z/04 (UK). We
gratefully acknowledge the resources provided by the Autism Genetic
Resource Exchange (AGRE) Consortium and the participating AGRE families.
The Autism Genetic Resource Exchange is a program of Autism Speaks and
is supported, in part, by grant 1U24MH081810 from the National Institute of
Mental Health to Clara M. Lajonchere (PI). Catarina Correia and Inês C.
Conceição are supported by grants SFRH/BPD/64281/2009 and SFRH/BPD/
74739/2010, respectively, from Fundação para a Ciência e Tecnologia.
Ethical approval was obtained from: i) the Ethics Committee at Hospital
Pediátrico de Coimbra (Portugal) for the Portuguese cases not included in
AGP; ii) the Ethics Committee at the Instituto Nacional de Saúde Doutor
Ricardo Jorge (Portugal) for the Portuguese controls; and iii) the Institutional
Review Board at UCLA for the AGRE sample. The control data from OHI,
approved by the Research Ethics Board of the University of Ottawa Heart
Institute; PopGen, approved by the Ethics Committee of the Medical Faculty
of Kiel and by the data protection officer of the University Hospital
Schleswig-Holstein; CHOP, approved by the Children’s Hospital of Philadelphia
Institutional Review Board; and SAGE, approved by the Institutional Review
Board at each contributing institution (COGA, FSCD, and COGEND) are
published and available. The AGP data involves several research centres and has
already been published; the data is available.
Author details
1Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon 1649-016,
Portugal. 2Center for Biodiversity, Functional & Integrative Genomics, Faculty
of Sciences, University of Lisbon, Lisbon 1749-016, Portugal. 3Instituto
Gulbenkian de Ciência, Oeiras 2780-156, Portugal. 4Unidade de
Neurodesenvolvimento e Autismo, Centro de Desenvolvimento da Criança e
Centro de Investigação e Formação Clínica, Hospital Pediátrico, Centro
Hospitalar e Universitário de Coimbra, Coimbra 3000-602, Portugal. 5Institute
for Biomedical Imaging and Life Sciences, Faculty of Medicine, University of
Coimbra, Coimbra 3000-548, Portugal. 6Autism Research Unit, The Hospital
for Sick Children and Bloorview Kids Rehab, University of Toronto, Toronto,
Ontario M5G 1X8, Canada. 7Program in Neurogenetics, Department of
Neurology, Center for Autism Research and Treatment, Semel Institute, David
Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. 8The
Centre for Applied Genomics and Program in Genetics and Genome Biology,
The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.
9Departments of Psychiatry, and Genetics and Genomic Sciences, Seaver
Autism Center, and the Mindich Child Health & Development Institute,
Mount Sinai School of Medicine, New York, NY 10029, USA. 10Institute of
Psychiatric Research, Departments of Psychiatry and Medical and Molecular
Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.11Department of Molecular Genetics and the McLaughlin Centre, University
of Toronto, Toronto, ON M5S 1A1, Canada.
Received: 26 August 2013 Accepted: 17 March 2014
Published: 10 April 2014References
1. Abrahams BS, Geschwind DH: Advances in autism genetics: on the
threshold of a new neurobiology. Nat Rev Genet 2008, 9:341–355.
2. Freitag CM, Staal W, Klauck SM, Duketis E, Waltes R: Genetics of autistic
disorders: review and clinical implications. Eur Child Adolesc Psychiatry
2010, 19:169–178.
3. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang H, Estes A,
Brune CW, Bradfield JP, Imielinski M, Frackelton EC, Reichert J, Crawford EL,
Munson J, Sleiman PM, Chiavacci R, Annaiah K, Thomas K, Hou C, Glaberson
W, Flory J, Otieno F, Garris M, Soorya L, Klei L, Piven J, Meyer KJ,
Anagnostou E, Sakurai T, et al: Autism genome-wide copy number
variation reveals ubiquitin and neuronal genes. Nature 2009, 459:569–573.
4. Autism Genome Project C, Szatmari P, Paterson AD, Zwaigenbaum L,
Roberts W, Brian J, Liu XQ, Vincent JB, Skaug JL, Thompson AP, Senman L,
Feuk L, Qian C, Bryson SE, Jones MB, Marshall CR, Scherer SW, Vieland VJ,
Bartlett C, Mangin LV, Goedken R, Segre A, Pericak-Vance MA, Cuccaro ML,
Gilbert JR, Wright HH, Abramson RK, Betancur C, Bourgeron T, Gillberg C,
Leboyer M, et al: Mapping autism risk loci using genetic linkage and
chromosomal rearrangements. Nat Genet 2007, 39:319–328.
5. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, Salyakina D,
Imielinski M, Bradfield JP, Sleiman PM, Kim CE, Hou C, Frackelton E,
Chiavacci R, Takahashi N, Sakurai T, Rappaport E, Lajonchere CM, Munson J,
Estes A, Korvatska O, Piven J, Sonnenblick LI, Alvarez Retuerto AI, Herman EI,
Dong H, Hutman T, Sigman M, Ozonoff S, Klin A, et al: Common genetic
variants on 5p14.1 associate with autism spectrum disorders. Nature
2009, 459:528–533.
6. Weiss LA, Arking DE, Daly MJ, Chakravarti A, Gene Discovery Project of
Johns Hopkins & the Autism Consortium: A genome-wide linkage and
association scan reveals novel loci for autism. Nature 2009, 461:802–808.
7. Betancur C: Etiological heterogeneity in autism spectrum disorders: more
than 100 genetic and genomic disorders and still counting. Brain Res
2011, 1380:42–77.
8. Buxbaum JD: Multiple rare variants in the etiology of autism spectrum
disorders. Dialogues Clin Neurosci 2009, 11:35–43.
9. Marshall CR, Scherer SW: Detection and characterization of copy number
variation in autism spectrum disorder. Methods Mol Biol 2012,
838:115–135.
10. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C,
Wang LS, Makarov V, Polak P, Yoon S, Maguire J, Crawford EL, Campbell NG,
Geller ET, Valladares O, Schafer C, Liu H, Zhao T, Cai G, Lihm J, Dannenfelser
R, Jabado O, Peralta Z, Nagaswamy U, Muzny D, Reid JG, Newsham I, Wu Y,
et al: Patterns and rates of exonic de novo mutations in autism spectrum
disorders. Nature 2012, 485:242–245.
11. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, Karakoc E,
Mackenzie AP, Ng SB, Baker C, Rieder MJ, Nickerson DA, Bernier R, Fisher SE,
Shendure J, Eichler EE: Exome sequencing in sporadic autism spectrum
disorders identifies severe de novo mutations. Nat Genet 2011,
43:585–589.
12. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A,
Lee C, Smith JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, Reilly B,
Akey JM, Borenstein E, Rieder MJ, Nickerson DA, Bernier R, Shendure J,
Eichler EE: Sporadic autism exomes reveal a highly interconnected
protein network of de novo mutations. Nature 2012, 485:246–250.
13. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J,
Magalhaes TR, Correia C, Abrahams BS, Almeida J, Bacchelli E, Bader GD,
Bailey AJ, Baird G, Battaglia A, Berney T, Bolshakova N, Bölte S, Bolton PF,
Bourgeron T, Brennan S, Brian J, Bryson SE, Carson AR, Casallo G, Casey J,
Chung BH, Cochrane L, Corsello C, et al: Functional impact of global rare
copy number variation in autism spectrum disorders. Nature 2010,
466:368–372.
14. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B,
Yoon S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R, Lee YH, Hicks J,
Spence SJ, Lee AT, Puura K, Lehtimäki T, Ledbetter D, Gregersen PK,
Bregman J, Sutcliffe JS, Jobanputra V, Chung W, Warburton D, King MC,
Correia et al. Molecular Autism 2014, 5:28 Page 13 of 14
http://www.molecularautism.com/content/5/1/28Skuse D, Geschwind DH, Gilliam TC, et al: Strong association of de novo
copy number mutations with autism. Science 2007, 316:445–449.
15. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J,
Andrews TD, Barnes C, Campbell P, Fitzgerald T, Hu M, Ihm CH, Kristiansson
K, Macarthur DG, Macdonald JR, Onyiah I, Pang AW, Robson S, Stirrups K,
Valsesia A, Walter K, Wei J, Wellcome Trust Case Control C, Tyler-Smith C,
Carter NP, Lee C, Scherer SW, Hurles ME: Origins and functional impact of
copy number variation in the human genome. Nature 2010, 464:704–712.
16. Malhotra D, Sebat J: CNVs: harbingers of a rare variant revolution in
psychiatric genetics. Cell 2012, 148:1223–1241.
17. Flower RJ, Blackwell GJ: Anti-inflammatory steroids induce biosynthesis of
a phospholipase A2 inhibitor which prevents prostaglandin generation.
Nature 1979, 278:456–459.
18. McArthur S, Cristante E, Paterno M, Christian H, Roncaroli F, Gillies GE, Solito
E: Annexin A1: a central player in the anti-inflammatory and
neuroprotective role of microglia. J Immunol 2010, 185:6317–6328.
19. Buckingham JC, John CD, Solito E, Tierney T, Flower RJ, Christian H, Morris J:
Annexin 1, glucocorticoids, and the neuroendocrine-immune interface.
Ann N Y Acad Sci 2006, 1088:396–409.
20. Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, Correia C,
Abrahams BS, Sykes N, Pagnamenta AT, Almeida J, Bacchelli E, Bailey AJ,
Baird G, Battaglia A, Berney T, Bolshakova N, Bölte S, Bolton PF, Bourgeron T,
Brennan S, Brian J, Carson AR, Casallo G, Casey J, Chu SH, Cochrane L,
Corsello C, Crawford EL, Crossett A, et al: A genome-wide scan for com-
mon alleles affecting risk for autism. Hum Mol Genet 2010, 19:4072–4082.
21. Stewart AF, Dandona S, Chen L, Assogba O, Belanger M, Ewart G, LaRose R,
Doelle H, Williams K, Wells GA, McPherson R, Roberts R: Kinesin family
member 6 variant Trp719Arg does not associate with angiographically
defined coronary artery disease in the Ottawa Heart Genomics Study.
J Am Coll Cardiol 2009, 53:1471–1472.
22. Krawczak M, Nikolaus S, von Eberstein H, Croucher PJ, El Mokhtari NE,
Schreiber S: PopGen: population-based recruitment of patients and
controls for the analysis of complex genotype-phenotype relationships.
Community Genet 2006, 9:55–61.
23. Bierut LJ, Agrawal A, Bucholz KK, Doheny KF, Laurie C, Pugh E, Fisher S, Fox
L, Howells W, Bertelsen S, Hinrichs AL, Almasy L, Breslau N, Culverhouse RC,
Dick DM, Edenberg HJ, Foroud T, Grucza RA, Hatsukami D, Hesselbrock V,
Johnson EO, Kramer J, Krueger RF, Kuperman S, Lynskey M, Mann K,
Neuman RJ, Nöthen MM, Nurnberger JI Jr, Porjesz B, et al: A genome-wide
association study of alcohol dependence. Proc Natl Acad Sci U S A 2010,
107:5082–5087.
24. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O'Hara R,
Casalunovo T, Conlin LK, D'Arcy M, Frackelton EC, Geiger EA, Haldeman-
Englert C, Imielinski M, Kim CE, Medne L, Annaiah K, Bradfield JP, Dabaghyan
E, Eckert A, Onyiah CC, Ostapenko S, Otieno FG, Santa E, Shaner JL, Skraban
R, Smith RM, Elia J, Goldmuntz E, Spinner NB, et al: High-resolution
mapping and analysis of copy number variations in the human genome:
a data resource for clinical and research applications. Genome Res 2009,
19:1682–1690.
25. Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, Bolshakova N, Bölte
S, Bolton PF, Bourgeron T, Brennan S, Brian J, Casey J, Conroy J, Correia C,
Corsello C, Crawford EL, de Jonge M, Delorme R, Duketis E, Duque F, Estes
A, Farrar P, Fernandez BA, Folstein SE, Fombonne E, Gilbert J, Gillberg C,
Glessner JT, Green A, et al: Individual common variants exert weak effects
on the risk for autism spectrum disorderspi. Hum Mol Genet 2012,
21:4781–4792.
26. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS, Seller A,
Holmes CC, Ragoussis J: QuantiSNP: an Objective Bayes Hidden-Markov
Model to detect and accurately map copy number variation using SNP
genotyping data. Nucleic Acids Res 2007, 35:2013–2025.
27. Oliveira G, Ataíde A, Marques C, Miguel TS, Coutinho AM, Mota-Vieira L,
Gonçalves E, Lopes NM, Rodrigues V, Carmona Da Mota H, Vicente AM:
Epidemiology of autism spectrum disorder in Portugal: prevalence,
clinical characterization, and medical conditions. Dev Med Child Neurol
2007, 49:726–733.
28. Constantino JN, Todd RD: Intergenerational transmission of subthreshold
autistic traits in the general population. Biol Psychiatry 2005, 57:655–660.
29. Hurley RS, Losh M, Parlier M, Reznick JS, Piven J: The broad autism
phenotype questionnaire. J Autism Dev Disord 2007, 37:1679–1690.
30. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 2000, 132:365–386.31. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M:
PennCNV: an integrated hidden Markov model designed for high-
resolution copy number variation detection in whole-genome SNP
genotyping data. Genome Res 2007, 17:1665–1674.
32. Bonfield JK, Smith K, Staden R: A new DNA sequence assembly program.
Nucleic Acids Res 1995, 23:4992–4999.
33. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud
C: Human Splicing Finder: an online bioinformatics tool to predict
splicing signals. Nucleic Acids Res 2009, 37:e67.
34. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A web
resource to identify exonic splicing enhancers. Nucleic Acids Res 2003,
31:3568–3571.
35. Matys V, Fricke E, Geffers R, Gössling E, Haubrock M, Hehl R, Hornischer K,
Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B,
Michael H, Münch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, Wingender
E: TRANSFAC: transcriptional regulation, from patterns to profiles.
Nucleic Acids Res 2003, 31:374–378.
36. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human
MicroRNA targets. PLoS Biol 2004, 2:e363.
37. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K,
Clawson H, Spieth J, Hillier LW, Richards S, Weinstock GM, Wilson RK, Gibbs
RA, Kent WJ, Miller W, Haussler D: Evolutionarily conserved elements in
vertebrate, insect, worm, and yeast genomes. Genome Res 2005,
15:1034–1050.
38. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler
D: The human genome browser at UCSC. Genome Res 2002, 12:996–1006.
39. Berg JM, Geschwind DH: Autism genetics: searching for specificity and
convergence. Genome Biol 2012, 13:247.
40. Yan J, Feng J, Craddock N, Jones IR, Cook EH, Goldman D, Heston LL, Chen
J, Burkhart P, Li W, Shibayama A, Sommer SS: Vitamin D receptor variants
in 192 patients with schizophrenia and other psychiatric diseases.
Neurosci Lett 2005, 380:37–41.
41. Liu X, Malenfant P, Reesor C, Lee A, Hudson ML, Harvard C, Qiao Y, Persico
AM, Cohen IL, Chudley AE, Forster-Gibson C, Rajcan-Separovic E, Lewis ME,
Holden JJ: 2p15-p16.1 microdeletion syndrome: molecular
characterization and association of the OTX1 and XPO1 genes with
autism spectrum disorders. Eur J Hum Genet 2011, 19:1264–1270.
42. Nachman MW, Crowell SL: Estimate of the mutation rate per nucleotide
in humans. Genetics 2000, 156:297–304.
43. Chelala C, Khan A, Lemoine NR: SNPnexus: a web database for functional
annotation of newly discovered and public domain single nucleotide
polymorphisms. Bioinformatics 2009, 25:655–661.
44. Cook EH, Scherer SW: Copy-number variations associated with
neuropsychiatric conditions. Nature 2008, 455:919–923.
45. Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, Gilliam
TC, Nowak NJ, Cook EH, Dobyns WB, Christian SL: Recurrent 16p11.2
microdeletions in autism. Hum Mol Genet 2008, 17:628–638.
46. Noor A, Whibley A, Marshall CR, Gianakopoulos PJ, Piton A, Carson AR, Orlic-
Milacic M, Lionel AC, Sato D, Pinto D, Drmic I, Noakes C, Senman L, Zhang
X, Mo R, Gauthier J, Crosbie J, Pagnamenta AT, Munson J, Estes AM, Fiebig
A, Franke A, Schreiber S, Stewart AF, Roberts R, McPherson R, Guter SJ, Cook
EH Jr, Dawson G, Schellenberg GD, et al: Disruption at the PTCHD1 Locus
on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci
Transl Med 2010, 2:49ra68.
47. Virkud YV, Todd RD, Abbacchi AM, Zhang Y, Constantino JN: Familial
aggregation of quantitative autistic traits in multiplex versus simplex
autism. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:328–334.
48. Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D, Lewis CM:
Penetrance for copy number variants associated with schizophrenia.
Hum Mol Genet 2010, 19:3477–3481.
49. Pickles A, Starr E, Kazak S, Bolton P, Papanikolaou K, Bailey A, Goodman R,
Rutter M: Variable expression of the autism broader phenotype: findings
from extended pedigrees. J Child Psychol Psychiatry 2000, 41:491–502.
50. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH,
Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A,
Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA,
Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH,
Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR,
Barrett TB, Bass N, et al: Genetic relationship between five psychiatric
disorders estimated from genome-wide SNPs. Nat Genet 2013,
45:984–994.
Correia et al. Molecular Autism 2014, 5:28 Page 14 of 14
http://www.molecularautism.com/content/5/1/2851. Consortium C-DGPG: Consortium GROoPG, Identification of risk loci with
shared effects on five major psychiatric disorders: a genome-wide
analysis. Lancet 2013, 381:1371–1379.
52. Nava C, Keren B, Mignot C, Rastetter A, Chantot-Bastaraud S, Faudet A,
Fonteneau E, Amiet C, Laurent C, Jacquette A, Whalen S, Afenjar A, Périsse
D, Doummar D, Dorison N, Leboyer M, Siffroi JP, Cohen D, Brice A, Héron D,
Depienne C: Prospective diagnostic analysis of copy number variants
using SNP microarrays in individuals with autism spectrum disorders. Eur
J Hum Genet 2014, 22:71–78.
53. Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, Itsara A, Vives
L, Walsh T, McCarthy SE, Baker C, Mefford HC, Kidd JM, Browning SR,
Browning BL, Dickel DE, Levy DL, Ballif BC, Platky K, Farber DM, Gowans GC,
Wetherbee JJ, Asamoah A, Weaver DD, Mark PR, Dickerson J, Garg BP,
Ellingwood SA, Smith R, Banks VC, Smith W, et al: A recurrent 16p12.1
microdeletion supports a two-hit model for severe developmental delay.
Nat Genet 2010, 42:203–209.
54. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G,
Konyukh M, Chaste P, Ey E, Rastam M, Anckarsäter H, Nygren G, Gillberg IC,
Melke J, Toro R, Regnault B, Fauchereau F, Mercati O, Lemière N, Skuse D,
Poot M, Holt R, Monaco AP, Järvelä I, Kantojärvi K, Vanhala R, Curran S,
Collier DA, Bolton P, Chiocchetti A, et al: Genetic and functional analyses
of SHANK2 mutations suggest a multiple hit model of autism spectrum
disorders. PLoS Genet 2012, 8:e1002521.
55. Conrad DF, Bird C, Blackburne B, Lindsay S, Mamanova L, Lee C, Turner DJ,
Hurles ME: Mutation spectrum revealed by breakpoint sequencing of
human germline CNVs. Nat Genet 2010, 42:385–391.
56. Kim PM, Lam HY, Urban AE, Korbel JO, Affourtit J, Grubert F, Chen X,
Weissman S, Snyder M, Gerstein MB: Analysis of copy number variants and
segmental duplications in the human genome: Evidence for a change in
the process of formation in recent evolutionary history. Genome Res 2008,
18:1865–1874.
57. Sun HT, Cohen S, Kaufmann WE: Annexin-1 is abnormally expressed in
fragile X syndrome: two-dimensional electrophoresis study in lymphocytes.
Am J Med Genet 2001, 103:81–90.
58. ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED,
Gunter C, Snyder M: An integrated encyclopedia of DNA elements in the
human genome. Nature 2012, 489:57–74.
59. Perretti M, D'Acquisto F: Annexin A1 and glucocorticoids as effectors of
the resolution of inflammation. Nat Rev Immunol 2009, 9:62–70.
60. Perretti M, Gavins FN: Annexin 1: an endogenous anti-inflammatory
protein. News Physiol Sci 2003, 18:60–64.
61. Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J,
Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B: Novel proteins
regulated by mTOR in subependymal giant cell astrocytomas of patients
with tuberous sclerosis complex and new therapeutic implications. Am J
Pathol 2010, 176:1878–1890.
62. Solito E, Kamal A, Russo-Marie F, Buckingham JC, Marullo S, Perretti M: A
novel calcium-dependent proapoptotic effect of annexin 1 on human
neutrophils. FASEB J 2003, 17:1544–1546.
63. Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev 2002,
82:331–371.
64. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P:
Macrocortin: a polypeptide causing the anti-phospholipase effect of
glucocorticoids. Nature 1980, 287:147–149.
65. Goines P, Van de Water J: The immune system's role in the biology of
autism. Curr Opin Neurol 2010, 23:111–117.
66. Pardo CA, Vargas DL, Zimmerman AW: Immunity, neuroglia and
neuroinflammation in autism. Int Rev Psychiatry 2005, 17:485–495.
67. Persico AM, Van de Water J, Pardo CA: Autism: where genetics meets the
immune system. Autism Res Treat 2012, 2012:486359.
68. Silva SC, Correia C, Fesel C, Barreto M, Coutinho AM, Marques C, Miguel TS,
Ataide A, Bento C, Borges L, Oliveira G, Vicente AM: Autoantibody
repertoires to brain tissue in autism nuclear families. J Neuroimmunol
2004, 152:176–182.
69. John CD, Christian HC, Morris JF, Flower RJ, Solito E, Buckingham JC:
Annexin 1 and the regulation of endocrine function. Trends Endocrinol
Metab 2004, 15:103–109.
70. Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates
KO, Barta PE, Pearlson GD: MRI volumes of amygdala and hippocampus in
non-mentally retarded autistic adolescents and adults. Neurology 1999,
53:2145–2150.71. Herbert J: Neurosteroids, brain damage, and mental illness. Exp Gerontol
1998, 33:713–727.
72. Hrdlicka M, Dudova I, Beranova I, Lisy J, Belsan T, Neuwirth J, Komarek V,
Faladova L, Havlovicova M, Sedlacek Z, Blatny M, Urbanek T: Subtypes of
autism by cluster analysis based on structural MRI data. Eur Child Adolesc
Psychiatry 2005, 14:138–144.
73. Palmen SJ, van Engeland H, Hof PR, Schmitz C: Neuropathological findings
in autism. Brain 2004, 127:2572–2583.
74. Rojas DC, Smith JA, Benkers TL, Camou SL, Reite ML, Rogers SJ:
Hippocampus and amygdala volumes in parents of children with autistic
disorder. Am J Psychiatry 2004, 161:2038–2044.
75. Waterhouse L, Fein D, Modahl C: Neurofunctional mechanisms in autism.
Psychol Rev 1996, 103:457–489.
76. Corbett BA, Mendoza S, Abdullah M, Wegelin JA, Levine S: Cortisol
circadian rhythms and response to stress in children with autism.
Psychoneuroendocrinology 2006, 31:59–68.
77. Corbett BA, Schupp CW, Levine S, Mendoza S: Comparing cortisol, stress,
and sensory sensitivity in children with autism. Autism Res 2009, 2:39–49.
78. Curin JM, Terzić J, Petković ZB, Zekan L, Terzić IM, Susnjara IM: Lower
cortisol and higher ACTH levels in individuals with autism. J Autism Dev
Disord 2003, 33:443–448.
79. Iwata K, Matsuzaki H, Miyachi T, Shimmura C, Suda S, Tsuchiya KJ,
Matsumoto K, Suzuki K, Iwata Y, Nakamura K, Tsujii M, Sugiyama T, Sato K,
Mori N: Investigation of the serum levels of anterior pituitary hormones
in male children with autism. Mol Autism 2011, 2:16.
80. Richdale AL, Prior MR: Urinary cortisol circadian rhythm in a group of
high-functioning children with autism. J Autism Dev Disord 1992,
22:433–447.
81. Morris JF, Omer S, Davies E, Wang E, John C, Afzal T, Wain S, Buckingham
JC, Flower RJ, Christian HC: Lack of annexin 1 results in an increase in
corticotroph number in male but not female mice. J Neuroendocrinol
2006, 18:835–846.
doi:10.1186/2040-2392-5-28
Cite this article as: Correia et al.: Recurrent duplications of the annexin
A1 gene (ANXA1) in autism spectrum disorders. Molecular Autism
2014 5:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
